Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three and nine months ended September 30, 2023 and 2022, respectively (in thousands, except share and per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Net loss attributable to Adaptive Biotechnologies Corporation	$	(50,300	)	$	(45,281	)	$	(155,809	)	$	(160,063	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		144,704,868			142,928,654			144,208,940			142,334,342
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(0.35	)	$	(0.32	)	$	(1.08	)	$	(1.12	)

Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and nine months ended September 30, 2023 and 2022, respectively, as they had an anti-dilutive effect:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Stock options outstanding		13,806,283		13,996,403		14,054,478		13,984,427
Nonvested restricted stock units outstanding		10,301,308		5,486,711		9,575,868		4,490,170
Maximum nonvested market-based restricted stock units outstanding eligible to be earned		1,912,674		494,234		1,580,146		381,990
Total		26,020,265		19,977,348		25,210,492		18,856,587